CRC tissue; adjacent normal tissue; tumour tissue; liver tissue; subcutaneous tumours
HCT116; SW480; HEK293T
cell line-derived xenograft
proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); EMT (promotes); ubiquitination (inhibits)
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; Microarray; ISH (In Situ Hybridization); IHC (Immunohistochemistry); IF (Immunofluorescence); Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Co-IP; Transfection; Colony Formation Assay; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; H&E Staining; Western Blot; Bioinformatics Analysis
Potential biomarker and therapeutic target for CRC diagnosis, prognosis, clinical treatment guidance, and metastatic CRC treatment.
circWBSCR22 (hsa_circ_0005588) is up-regulated in colorectal cancer tissues and functions as an oncogenic circRNA. It promotes CRC proliferation, migration, invasion, EMT, tumour growth, and metastasis by binding UPF1 and reducing UPF1-mediated ubiquitination degradation of CHD4, thereby stabilizing CHD4 protein. The study proposes circWBSCR22 as a potential diagnostic/prognostic biomarker and therapeutic target for CRC.
0.8817
Circular RNA circWBSCR22 facilitates colorectal cancer metastasis by enhancing CHD4's protein stability.
combined biological and clinical study